Gruppo Oncologico Italiano Di Ricerca Clinica

This study tests a combination of the immunotherapy drug cemiplimab plus chemotherapy in people with advanced squamous non-small cell lung cancer who have not had prior treatment. The treatment is chosen based on a biomarker called cytidine deaminase activity. The main goal is to…

This study tests whether the drug avelumab can help people with advanced bladder cancer that has spread (metastatic urothelial carcinoma) live longer without their cancer getting worse. Participants will have already received two prior treatments, including chemotherapy, and then…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (XELOX) after chemoradiation helps shrink advanced rectal cancer more than chemotherapy alone. About 270 adults with a specific type of rectal cancer (pMMR/MSS or MSI-Low) will take part. …

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced kidney cancer (clear cell type) whose disease got worse after prior immunotherapy. About 108 adults will receive the treatment to see if it shrinks tumors or delays cancer growth. T…

This study looks at 150 adults aged 18 to 49 who have been newly diagnosed with early-onset gastrointestinal cancer. Researchers will collect information on the cancer's features, patients' lifestyle habits, and how the disease progresses over 12 months. The goal is to better und…